Cargando…

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease

OBJECTIVE: To determine clinical and biological variables that predict time to initiation of symptomatic therapy in de novo Parkinson's disease patients. METHODS: Parkinson's Progression Markers Initiative is a longitudinal case–control study of de novo, untreated Parkinson's disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simuni, Tanya, Long, Jeffrey D., Caspell‐Garcia, Chelsea, Coffey, Christopher S., Lasch, Shirley, Tanner, Caroline M., Jennings, Danna, Kieburtz, Karl D., Marek, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931714/ https://www.ncbi.nlm.nih.gov/pubmed/27386498 http://dx.doi.org/10.1002/acn3.317

Ejemplares similares

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Identifying prodromal symptoms at high specificity for Parkinson’s disease
por: Jackson, Holly, et al.
Publicado: (2023)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
por: Atri, Roozbeh, et al.
Publicado: (2022)

Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
por: Vaswani, Pavan A., et al.
Publicado: (2023)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience
por: Dobkin, Roseanne D., et al.
Publicado: (2020)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Self-triggered assistive stimulus training improves step initiation in persons with Parkinson’s disease
por: Creath, Robert A, et al.
Publicado: (2013)

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease
por: Paracha, Mariam, et al.
Publicado: (2022)

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
por: Venuto, Charles S., et al.
Publicado: (2021)

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021)

A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease
por: Larson, Danielle N., et al.
Publicado: (2021)

Trichloroethylene: An Invisible Cause of Parkinson’s Disease?
por: Dorsey, E. Ray, et al.
Publicado: (2023)

Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
por: Chahine, Lana M., et al.
Publicado: (2020)

CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON’S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA’S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES
por: McFarthing, Kevin, et al.
Publicado: (2019)

Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
por: Tosin, Michelle H.S., et al.
Publicado: (2022)

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021)

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease
por: Hayete, Boris, et al.
Publicado: (2017)

Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments
por: Brundin, Patrik, et al.
Publicado: (2013)

Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson’s Disease patients assessed using pseudo-continuous arterial spin labeling
por: Chen, Yufen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ahitg23pvi602b2a989ob05l67